AbCellera Results Presentation Deck slide image

AbCellera Results Presentation Deck

FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 $101.4M total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $5.5M $5.1M Q3 2021 $101.4M $93.3M $7.5M Q3 2022
View entire presentation